A new weight-loss medication from Eli Lilly has shown significant benefits in improving cardiovascular health. The findings, published in a medical journal, suggest that the drug can reduce the risk of heart attacks and strokes in patients with type 2 diabetes.
This news comes as a setback for Novo Nordisk, another major pharmaceutical company, which had been developing its own weight-loss treatment to tackle obesity-related health issues. While Novo Nordisk’s product has yet to receive regulatory approval, its failure to deliver on cardiovascular benefits may impact its chances of success in the market.
Source: https://www.barrons.com/articles/elli-lilly-mounjaro-cardio-novo-nordisk-c375820f